Iinzuzo kunye neempembelelo ezingasemva
I-Hydroxyzine isizukulwana sokuqala, i- antihistamine , echaza ukuba ineziphumo ezifanayo kwiBenadryl . Ithengiswa phantsi kwegama legama le-Atarax neVistaril kodwa lifumaneka nakwifomu yobudala. I-Hydroxyzine yayisungulwa ekuqaleni njenge-sedative ngexesha lama-1950 kodwa ifunyenwe ukuba ne-antihistamine.
Hydroxyzine for Allergies
I-Hydroxyzine ifakwe ngokuqhelekileyo kunyango lweemeko ezahlukeneyo, ngokukodwa imingxuma , kodwa isetyenziswa ngokuqhelekileyo ukuphathwa, ukuxhala, ukulala, kunye nokuhlanjululwa kunye nokuhlanza.
I dose ye-hydroxyzine incike kwimeko ephathwayo, nangona idosi eqhelekileyo i-25 ukuya kuma-50 milligram nganye kwiiyure ezithandathu. I-Hydroxyzine isetyenziselwa abantwana, nangona idosi ibalwa ngokusekelwe kumlinganiselo womntwana. Nangona kunjalo, imiphumo yesalathiso nokulalazela kunokukhokelela ekugqithweni kwemithi yesinye sezizukulwane zesibini zokuzala njenge-Xyzal (levocetirizine.)
Indlela iHydroxyzine isebenza ngayo i-Allergies
I-Hydroxyzine isebenza ngokukhusela i-H1 receptor, ibopha kubo kwaye iyancipha umsebenzi we-histamine. I-Histamine ivumela ukuba amanzi amaninzi aphunyuke kwii-capillaries zibe ngamathishu, kwaye yilo lukhuni olunezimpumlo kunye neyamehlo xa unesifo esiphezulu. I-Histamine ikhuthaza ukuvuvukala kunye nokuveliswa kwevili kuma-rashes.
Ngokuthintela i-H1 receptor, i-hydroxyzine isebenza ngokubhekiselele kule miqondiso yezilwanyana. Oku kunokukunceda xa ukubetha (pruritis) kubangelwa ukugula.
Kodwa i-hydroxyzine nayo iwela engqondweni apho ineziphumo ezingaphezulu zokubangela ukulala nokungqungquthela. Le miphumo ayinakufunwa xa uphatha unyango.
I-Anti-Generation Generation Antihistamines Ephuma Kwi-Hydroxyzine
I-metabolite esebenzayo ye-hydroxyzine yi- cetirizine (i-Zyrtec) , efumaneka kwi-counter-counter-anti-anti-stistamine.
Umsetyenzana osebenzayo we-cetirizine yi- levocetirizine (i-Xyzal) , efumaneka kuphela ngomyalelo kwaye sele ifumaneka kwifomu yobudala. Awuweleli ingqondo njengokuba i-hydroxyzine, kwaye ngoko ayiyikuvelisa i-sedation efanayo. Ayikuvelisa iziphumo ezixhatshazelisayo ze-hydroxyzine ngesizathu esifanayo.
I-Zyrtec kunye ne-Xyzal zilungele ukonyango lwe-rhinitis ephezulu kune-hydroxyzine kuba zinemiphumo embalwa kunye nexesha elide lokuthatha isenzo. Ziye zisebenza ngonyango lwemikoko kunye nokutshiza.
I-Zyrtec kunye ne-Xyzal ayinakulungiselela unyango lwexhala, ukulala okanye ukuxubha, kunye nokuhlanza, iimeko apho i-hydroxyzine okanye enye i-antihistamine yokuzalwa yokuqala ingayimiswa. (Nangona i-hydroxyzine ibe yimithi eneminyaka engama-50 ubudala, isenceda ngokunyanga kweemeko ezahlukeneyo zonyango.)
Ukuhlaziywa kweengxelo ze-Xyzal (levocetirizine) ngo-2009 kwafumanisa ukuba i-5 mg / d yayiphumelele ekunciphiseni iimpawu ze-rhinitis ye-allergen ( hay fever ,) i-rhinitis yokugula engapheliyo, kunye ne-idiopathic urticaria (engapheliyo emangcwabeni engaziwayo, ukuphucula umgangatho ubomi, kunye neprofayili yokunyamezela).
Ngaphantsi kweMvelaphi yesiBini kwi-Anti-stistamines yokuqala yesizukulwana
Inzuzo ye-antihistamines yesizukulwana sesibini (iZyrtec kunye no-Xyzal) ukungabikho kwemiphumo engafunekiyo efana ne-sedation, ukulala, nobunzima bokugxila nokufunda.
Ezi ziphumo zempembelelo zixhalabise ngakumbi xa abantwana abaneminyaka esikolweni baphathwa ixesha elide kunye ne-hydroxyzine.
I-Xyzal (levocetirizine) yiyo kuphela i-antihistamine engabikho miphumo echaphazelekayo ekliniki ekuphuculeni ngokomzimba nangokwenzululwazi kubantwana abaneminyaka eli-6 ukuya kwe-12, ngokweengxelo.
Okokuthi, i-hydroxyzine iyaqhubeka ingenayo ingxaki yokusebenzisa i-allergies ekunyangeni ukuxhalaba, ukulala, kunye nokuhlanjululwa. Kungenzeka nokuba yimithi emfutshane yangexesha elifutshane kubantu abadala abanomdla xa iziphumo zesalathisi zinokuba luncedo (ezifana nokungazinzi okanye ukukhathazeka.)
> Imithombo:
> Pampura, A., Papadopoulos, N., Spicak, V., no R. Kurzawa. Ubungqina boKhuseleko lweZikliniki, uLobuchule, kunye noMzali kunye neNtsholongwane ye-Levocetirizine yokuPhatha kwaBantwana abanezifo ezigugu. IiNcwadi zoLondolozo lweeNkcukacha zamazwe ngamazwe we-Allergy and Immunology 2011. 155 (4): 367-78.